My UM
My UM
Search

Gerardus Bos (G.M.J.)

Recent publications
  • Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024). Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Practice & Research Clinical Haematology, 37(3), Article 101568. https://doi.org/10.1016/j.beha.2024.101568
    More information about this publication
  • Gong, Y., Germeraad, W. T. V., Zhang, X., Wu, N., Li, B., Janssen, L., He, Z., Gijbels, M. J. J., Wu, B., Gijsbers, B. L. M. G., Olieslagers, T. I., Bos, G. M. J., Zheng, L., & Klein Wolterink, R. G. J. (2024). NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Molecular Therapy, 32(8), 2711-2727. https://doi.org/10.1016/j.ymthe.2024.06.034
    More information about this publication
  • Minnema, M. C., Nasserinejad, K., Hegenbart, U., Ypma, P. F., Wu, K. L., Kersten, M. J., Croockewit, S., Zweegman, S., Tick, L., Broijl, A., Koene, H., Bos, G. M. J., Sonneveld, P., & Schonland, S. O. (2024). HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients. eJHaem, 5(4), 815-819. https://doi.org/10.1002/jha2.918
    More information about this publication
  • Beelen, N. A., Molenbroeck, S. J. J., Groeneveld, L., Voorter, C. E., Bos, G. M. J., & Wieten, L. (2024). HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma. Immunogenetics, 76(3), 155-164. https://doi.org/10.1007/s00251-024-01336-w
    More information about this publication
  • Beelen, N. A., Aberle, M. R., Bruno, V., Olde Damink, S. W. M., Bos, G. M. J., Rensen, S. S., & Wieten, L. (2023). Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology, 14(1), Article 1133796. https://doi.org/10.3389/fimmu.2023.1133796
    More information about this publication
  • Ehlers, F. A. I., Mahaweni, N. M., van de Waterweg Berends, A., Saya, T., Bos, G. M. J., & Wieten, L. (2023). Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunology Immunotherapy, 72(6), 1789-1801. https://doi.org/10.1007/s00262-022-03365-4
    More information about this publication
  • Verkleij, C. P. M., Frerichs, K. A., Broekmans, M. E. C., Duetz, C., O'Neill, C. A., Bruins, W. S. C., Homan-Weert, P. M., Minnema, M. C., Levin, M. D., Broijl, A., Bos, G. M. J., Kersten, M. J., Klein, S. K., Shikhagaie, M. M., Casneuf, T., Abraham, Y., Smets, T., Vanhoof, G., Cortes-Selva, D., ... van de Donk, N. W. C. J. (2023). NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma. HemaSphere, 7(5), Article e881. https://doi.org/10.1097/HS9.0000000000000881
    More information about this publication
  • Beelen, N. A., Ehlers, F. A. I., Bos, G. M. J., & Wieten, L. (2023). Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology Immunotherapy, 72(4), 797-804. https://doi.org/10.1007/s00262-022-03299-x
    More information about this publication
  • Beelen, N. A., Ehlers, F. A. I., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2023). An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. In C. Thomas, & L. Galluzzi (Eds.), The Immunological Synapse Part A (1 ed., Vol. 173, pp. 133-153). Academic Press. https://doi.org/10.1016/bs.mcb.2022.05.001
    More information about this publication
  • van Gorkom, G. N. Y., Boerenkamp, L. S., Gijsbers, B. L. M. G., van Ojik, H. H., Wodzig, W. K. W. H., Wieten, L., Van Elssen, C. H. M. J., & Bos, G. M. J. (2022). No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial. Nutrients, 14(22), Article 4784. https://doi.org/10.3390/nu14224784
    More information about this publication
Go to all publications